Analginum - Darnitsa, the tab. till 0:5ú No. 10

General characteristics. Structure:

Active ingredient: metamizole sodium;

1 tablet contains 500 mg of metamizole sodium (analginum);

excipients: potato starch, talc, calcium stearate.

Pharmacological properties:

Derivative pyrazyl ketone, cyclooxygenase blocker. Reduces formation of prostaglandins from arachidonic acid. Differs from other blockers of cyclooxygenase in slightly expressed antiinflammatory effect, at the expressed analgetichesky, febrifugal and spasmolytic action. Spasmolytic action is shown on smooth muscles of urinary and bilious tract.

Interferes with carrying out painful extra-and proprioretseptivny impulses on Gaulle and Burdakh's bunches, raises an excitation threshold of the thalamic centers of painful sensitivity, increases a thermolysis.

It is quickly soaked up from digestive tract. In a wall of intestines it is hydrolyzed with formation of an active metabolite. In not changed look in blood is absent. The active metabolite for 50-60% contacts proteins of a blood plasma. Time of achievement of the maximum concentration in a blood plasma makes 1-2 hours. An elimination half-life (T1/2) – 2,5 hours. It is removed generally by kidneys.

Indications to use:

Pain syndrome of various origin: head, a dentagra, neuralgia, radiculitis, a miositis, pains during periods. As supportive application can be applied to reduction of pain after surgical and diagnostic interventions. Hyper thermal syndrome.

Route of administration and doses:

Pill is taken after food, washing down with a small amount of water.

To adults and children aged from 14 years usually appoint on ½-1 tablet 1-2 times a day.

The maximum daily dose – 1000 mg.

To children aged from 12 up to 14 years – on ½ tablets 1-2 times a day.

Duration of treatment makes no more than 3 days.

Features of use:

Use during pregnancy or feeding by a breast.

Drug is contraindicated during pregnancy, during treatment it is necessary to stop feeding by a breast.

Ability to influence speed of response at control of motor transport or work with other mechanisms.

Does not influence.

Children.

Drug is not appointed to children up to 12 years.

Side effects:

Allergic reactions: seldom – skin rash, a Quincke's edema, Stephens-Johnson's syndrome, a Lyell's disease, an acute anaphylaxis, a small tortoiseshell.

From blood: thrombocytopenia, granulocytopenia, leukopenia, anemia; in isolated cases – an agranulocytosis.

From an urinary system: intersticial nephrite, oliguria, anury.

From biliary system: hepatitis.

From respiratory system: at tendency to a bronchospasm provoking of an attack is possible.

Interaction with other medicines:

Ethanol – strengthens effect of ethanol.

Chlorpromazinum or other derivatives of a fenotiazin – simultaneous use can lead to development of the expressed hypothermia.

Radiopaque substances, colloid blood substitutes and penicillin – should not be applied during treatment by analginum.

Cyclosporine – at simultaneous use decreases concentration of cyclosporine in blood.

Peroral hypoglycemic drugs, indirect anticoagulants, glucocorticosteroids and indometacin – analginum increases activity of these drugs by replacement them from communication with protein.

Phenylbutazone, barbiturates and other gepatoinduktor – at simultaneous use reduce efficiency of analginum.

Non-narcotic analgesics, tricyclic antidepressants, hormonal contraceptives and Allopyrinolum – simultaneous use of analginum with these drugs can lead to strengthening of its toxicity.

Sedatives and tranquilizers (Sibazonum, Trioxazinum, valocordin) – strengthen the anesthetizing effect of analginum.

Thiamazolum and sarcolysine – increase risk of development of a leukopenia.

Codeine, histamine H2 blockers and propranolol – strengthen effect of analginum.

Care at simultaneous use of drug with sulfanamide glucose-lowering drugs (hypoglycemic action amplifies) and diuretics is necessary (furosemide).

Contraindications:

Hypersensitivity to drug components, pyrazyl ketone derivatives. Changes of composition of peripheral blood: agranulocytosis, leukopenia. Blood diseases: anemia of any etiology, cytostatic or infectious neutropenia. Pregnancy, feeding period breast. The expressed changes of function of a liver and kidneys (porphyrinic exchange). Inborn insufficiency glyukozo-6-fosfatdegidrogenazy. Bronchial asthma. Suspicion of acute surgical pathology. Children's age up to 12 years.

Necessary security measures at use.

At use to children constant medical control has to be carried out. It is necessary to control qualitative and quantitative composition of peripheral blood. At identification of unmotivated temperature increase, a fever, pharyngalgia, difficulty of swallowing, stomatitis, at development of a vaginitis or proctitis administration of drug should be stopped immediately.

Not to use drug for removal of an acute pain in a stomach (before clarification of the reason).

With care apply at diseases of kidneys (pyelonephritis, a glomerulonephritis), allergic diseases and at the long alcoholic anamnesis.

At use of analginum coloring of urine in red color in connection with allocation of a metabolite is possible.

Overdose:

Nausea, vomiting, gastralgia, oliguria, anury, hypothermia, lowering of arterial pressure, tachycardia, short wind, sonitus, drowsiness, weakness, nonsense, consciousness disturbance, acute agranulocytosis, acute renal or liver failure, hemorrhagic syndrome, spasms, paralysis of respiratory muscles.

Treatment. Induction of vomiting or a probe gastric lavage, purpose of salt laxative, absorbent carbon, carrying out an artificial diuresis, and in hard cases – a hemodialysis is possible.

Storage conditions:

To store in the place, unavailable to children, in original packaging at a temperature not over 25 a validity °s.srok - 5 years.

Issue conditions:

Without recipe

Packaging:

On 10 tablets in a blister strip packaging; on 1 blister strip packaging in a pack; on 10 tablets in blister strip packagings.